A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?

Atherosclerosis

Volumn 230, Issue 2, 2013, Pages 258-267

  Oni, Ebenezer T ^a   Agatston, Arthur S ^a,b   Blaha, Michael J ^c   Fialkow, Jonathan ^d   Cury, Ricardo ^b,d   Sposito, Andrei ^e   Erbel, Raimund ^f   Blankstein, Ron ^g   Feldman, Ted ^a   Al Mallah, Mouaz H ^h   Santos, Raul D ⁱ   Budoff, Matthew J ^j   Nasir, Khurram ^a,b,c,k  

^a Baptist Health South Florida   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BAPTIST HOSPITAL OF MIAMI   (United States)

^e UNIVERSITY OF CAMPINAS   (Brazil)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF SÃO PAULO   (Brazil)

^j HARBOR UCLA MEDICAL CENTER   (United States)

^k FLORIDA INTERNATIONAL UNIVERSITY   (United States)

more..

Author keywords

Arterial stiffness; Carotid intima media thickness (CIMT); Coronary calcification; Endothelial dysfunction; Pulse wave velocity

Indexed keywords

ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; BODY BURDEN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; HUMAN; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ARTERIAL STIFFNESS; CAROTID INTIMA MEDIA THICKNESS (CIMT); CORONARY CALCIFICATION; ENDOTHELIAL DYSFUNCTION; PULSE WAVE VELOCITY;

ARTERIES; CALCINOSIS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHRONIC DISEASE; FATTY LIVER; HUMANS; OBESITY; PREVALENCE; RISK FACTORS; VASCULAR STIFFNESS;

EID: 84884508163     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.07.052     Document Type: Review

References (86)

1. Adams L.A., Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005, 22(9):1129-1133.
2. McCullough A.J. Pathophysiology of nonalcoholic steatohepatitis. JClin Gastroenterol 2006, 40(Suppl.1):S17-S29.
3. Marchesini G., Marzocchi R., Agostini F., Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005, 16(4):421-427.
4. Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005, 330(6):326-335.
5. Targher G., Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191(2):235-240.
6. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. The Lancet 2005, 365(9468):1415-1428.
7. Ndumele C.E., Nasir K., Conceicao R.D., Carvalho J.A., Blumenthal R.S., Santos R.D. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol 2011, 31(8):1927-1932.
8. Stefan N., Kantartzis K., Haring H.U. Causes and metabolic consequences of Fatty liver. Endocr Rev 2008, 29(7):939-960.
9. Kim H.J., Kim H.J., Lee K.E., et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004, 164(19):2169-2175.
10. Toledo F.G., Sniderman A.D., Kelley D.E. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006, 29(8):1845-1850.
11. Adiels M., Taskinen M.R., Boren J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 2008, 8(1):60-64.
12. DeFilippis A.P., Blaha M.J., Martin S.S., et al. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis 2013, 227(2):429-436.
13. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. NEngl J Med 2010, 363(14):1341-1350.
14. Targher G., Bertolini L., Padovani R., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30(5):1212-1218.
15. Targher G., Bertolini L., Padovani R., et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. JHepatol 2010, 53(4):713-718.
16. Stefan N., Kantartzis K., Machann J., et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008, 168(15):1609-1616.
17. Fuchs M., Sanyal A.J. Lipotoxicity in NASH. JHepatol 2012, 56(1):291-293.
18. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. NEngl J Med 2002, 347(20):1557-1565.
19. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108(19):2317-2322.
20. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998, 98(21):2241-2247.
21. Stefan N., Haring H.U. The role of hepatokines in metabolism. Nat Rev Endocrinol 2013, 9(3):144-152.
22. Stefan N., Haring H.U. The metabolically benign and malignant fatty liver. Diabetes 2011, 60(8):2011-2017.
23. Lehmann R., Franken H., Dammeier S., et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 2013 March 20, [Epub ahead of print].
24. Rittig K., Thamer C., Haupt A., et al. High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis 2009, 207(2):341-342.
25. Targher G., Bertolini L., Padovani R., Zenari L., Zoppini G., Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004, 27(10):2498-2500.
26. Brea A., Mosquera D., Martin E., Arizti A., Cordero J.L., Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005, 25(5):1045-1050.
27. Volzke H., Robinson D.M., Kleine V., et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005, 11(12):1848-1853.
28. Aygun C., Kocaman O., Sahin T., et al. Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2008, 53(5):1352-1357.
29. Fracanzani A.L., Burdick L., Raselli S., et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008, 121(1):72-78.
30. McKimmie R.L., Daniel K.R., Carr J.J., et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008, 103(12):3029-3035.
31. Kim H.C., Kim D.J., Huh K.B. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009, 204(2):521-525.
32. Petit J.M., Guiu B., Terriat B., et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. JClin Endocrinol Metab 2009, 94(10):4103-4106.
33. Salvi P., Ruffini R., Agnoletti D., et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. JHypertens 2010, 28(8):1699-1707.
34. Vlachopoulos C., Manesis E., Baou K., et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study. Am J Hypertens 2010, 23(11):1183-1189.
35. Dogru T., Genc H., Tapan S., et al. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease?. Diabetes Res Clin Pract 2012, 96(1):47-52.
36. Mohammadi A., Bazazi A., Ghasemi-Rad M. Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease. Int J Gen Med 2011, 4:717-722.
37. Colak Y., Karabay C.Y., Tuncer I., et al. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012, 24(6):613-618.
38. Colak Y., Senates E., Yesil A., et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013, 43(1):100-107.
39. Huang Y., Bi Y., Xu M., et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler Thromb Vasc Biol 2012, 32(9):2321-2326.
40. Thakur M.L., Sharma S., Kumar A., et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis 2012, 223(2):507-511.
41. Akabame S., Hamaguchi M., Tomiyasu K., et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J 2008, 72(4):618-625.
42. Santos R.D., Nasir K., Conceicao R.D., Sarwar A., Carvalho J.A., Blumenthal R.S. Hepatic steatosis is associated with a greater prevalence of coronary artery calcification in asymptomatic men. Atherosclerosis 2007, 194(2):517-519.
43. Assy N., Djibre A., Farah R., Grosovski M., Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010, 254(2):393-400.
44. Chen C.H., Nien C.K., Yang C.C., Yeh Y.H. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010, 55(6):1752-1760.
45. Kim D., Choi S.Y., Park E.H., et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012, 56(2):605-613.
46. Jung D.H., Lee Y.J., Ahn H.Y., Shim J.Y., Lee H.R. Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification. Clin Chem Lab Med 2010, 48(12):1829-1834.
47. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42(2):473-480.
48. Senturk O., Kocaman O., Hulagu S., et al. Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. Intern Med J 2008, 38(3):183-189.
49. Sciacqua A., Perticone M., Miceli S., et al. Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. Nutr Metab Cardiovasc Dis 2011, 21(7):485-491.
50. Mohammadi A., Sedani H.H., Ghasemi-Rad M. Evaluation of carotid intima-media thickness and flow-mediated dilatation in middle-aged patients with nonalcoholic fatty liver disease. Vasc Health Risk Manag 2011, 7:661-665.
51. Isilak Z., Aparci M., Kardesoglu E., et al. Abnormal aortic elasticity in patients with liver steatosis. Diabetes Res Clin Pract 2010, 87(1):44-50.
52. Catena C., Bernardi S., Sabato N., et al. Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. Nutr Metab Cardiovasc Dis 2013, 23(4):389-393.
53. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012, 107(6):811-826.
54. Mishra P., Younossi Z.M. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 2007, 102(12):2716-2717.
55. Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 2012 Nov 8, [Epub ahead of print].
56. Kim B.J., Kim N.H., Kim B.S., Kang J.H. The association between nonalcoholic fatty liver disease, metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals. Cardiology 2012, 123(1):54-61.
57. Cobble M., Bale B. Carotid intima-media thickness: knowledge and application to everyday practice. Postgrad Med 2010, 122(1):10-18.
58. Hamirani Y.S., Pandey S., Rivera J.J., et al. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 2008, 201(1):1-7.
59. Braun J., Oldendorf M., Moshage W., Heidler R., Zeitler E., Luft F.C. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996, 27(3):394-401.
60. O'Malley P.G., Taylor A.J., Jackson J.L., Doherty T.M., Detrano R.C. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol 2000, 85(8):945-948.
61. Sangiorgi G., Rumberger J.A., Severson A., et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. JAm Coll Cardiol 1998, 31(1):126-133.
62. Arad Y., Spadaro L.A., Goodman K., et al. Predictive value of electron beam computed tomography of the coronary arteries. 19-Month follow-up of 1173 asymptomatic subjects. Circulation 1996, 93(11):1951-1953.
63. Desai C.S., Ning H., Kang J., et al. Competing cardiovascular outcomes associated with subclinical atherosclerosis (from the multi-ethnic study of atherosclerosis). Am J Cardiol 2013, 111(11):1541-1546.
64. Gorgui J., Doonan R.J., Gomez Y.H., Kwong C., Daskalopoulou S.S. Carotid endarterectomy improves peripheral but not central arterial stiffness. Eur J Vasc Endovasc Surg 2013, 45(6):548-553.
65. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. JAm Coll Cardiol 2010, 55(13):1318-1327.
66. Bhatia L.S., Curzen N.P., Calder P.C., Byrne C.D. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 2012, 33(10):1190-1200.
67. Sookoian S., Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. JHepatol 2008, 49(4):600-607.
68. Bhatia L.S., Curzen N.P., Byrne C.D. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol 2012, 27(4):420-428.
69. Kopec K.L., Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract 2011, 26(5):565-576.
70. Ruhl C.E., Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003, 124(1):71-79.
71. Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002, 35(2):367-372.
72. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120(5):1183-1192.
73. Choi S.Y., Kim D., Kim H.J., et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 2009, 104(8):1953-1960.
74. Targher G., Bertolini L., Poli F., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54(12):3541-3546.
75. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51(11):1947-1953.
76. Sung K.C., Wild S.H., Kwag H.J., Byrne C.D. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 2012, 35(11):2359-2364.
77. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 2007, 24(1):1-6.
78. McCullough A.J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004, 8(3):521-533. viii.
79. Racial/ethnic and socioeconomic disparities in multiple risk factors for heart disease and stroke - United States, 2003. MMWR Morb Mortal Wkly Rep 2005, 54(5):113-117.
80. Mensah G.A., Mokdad A.H., Ford E.S., Greenlund K.J., Croft J.B. State of disparities in cardiovascular health in the United States. Circulation 2005, 111(10):1233-1241.
81. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. Aposition statement on NAFLD/NASH based on the EASL 2009 special conference. JHepatol 2010, 53(2):372-384.
82. Friedrich-Rust M., Schlueter N., Smaczny C., et al. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. JCyst Fibros 2013 Jan 26, [Epub ahead of print].
83. Ferdinand K.C. Coronary artery disease in minority racial and ethnic groups in the United States. Am J Cardiol 2006, 97(2A):12A-19A.
84. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
85. Liu J., Fox C.S., Hickson D., Bidulescu A., Carr J.J., Taylor H.A. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol 2011, 31(11):2715-2722.
86. Nestel P.J., Mensink R.P. Perspective: nonalcoholic fatty liver disease and cardiovascular risk. Curr Opin Lipidol 2013, 24(1):1-3.